Attached files
PAGE 1
Investor Fact Sheet
Ticker Symbol: NASDAQ: CEMI
www.chembio.com
Business Summary & Investment Highlights
Chembio Diagnostics, Inc., (Chembio), through its wholly-owned subsidiary Chembio Diagnostic Systems, Inc. develops, manufactures, licenses and markets point-of-care testing (POCT) products. Chembio created and patented a new revolutionary technology called Dual Path Platform (DPP®). The technology is addressing critical market requirements in the infectious diseases testing market and other growing markets. Products under development, both OEM and branded, are anticipated to create significant new revenue streams that will add to Chembio’s core business of rapid HIV tests.
|
·
|
Three Consecutive Years of Profitability and Revenue Growth
|
|
·
|
Strategy is to create core business of public health and women’s health products to be complemented by OEM and selected out-licensing opportunities.
|
|
·
|
Robust pipeline of POCT products for infectious diseases based on Chembio’s patented DPP® technology.
|
|
·
|
Products developed on DPP® platform include oral fluid HIV test anticipated to be reviewed by FDA during 2012. Unique Syphilis tests will be submitted and undergoing US FDA regulatory evaluations in 2012. Several other products and collaborations in pipeline.
|
|
·
|
Unique opportunity to participate in nascent U.S. market for OTC HIV tests with multiple product offerings.
|
|
·
|
Five DPP® products approved in Brazil during 2010-11 are anticipated to generate at least $9MM in 2012 revenues as compared with $4.5MM in 2011.
|
Selected Financial Information
Stock Information
Ticker Symbol: CEMI
Price 10/31/2012 $4.36
52 Week High $5.30
52 Week Low $2.96
Outstanding Shares (MM) 8.0
Market Capitalization (MM) $34.9
Fully Diluted (FD) Shares (MM) 8.8
Management Holding-FD (MM): 1.6
Average Daily Vol. (3 Mos) 27,400
Major Beneficial Holders Beneficial Shares Owned (MM)
Lawrence Siebert: 894
|
Balance Sheet Data ($000s)
|
Sept’12
|
Dec ‘11
|
|
Cash
|
$3,290
|
$ 3,011
|
|
Accts. Receivable
|
2,567
|
2,998
|
|
Inventories
|
3,038
|
2,300
|
|
Other Current Assets
|
706
|
682
|
|
Total Current Assets
|
9,601
|
8,991
|
|
Net Fixed Assets
|
1,335
|
1,062
|
|
Other Assets
|
5,204
|
5,432
|
|
Total Assets
|
16,140
|
15,486
|
|
Total Current Liab.
|
2,761
|
2,858
|
|
Total Other Liab.
|
95
|
133
|
|
Total Liabilities
|
2,856
|
2,991
|
|
Total Equity
|
13,284
|
12,495
|
|
Total Liabilities & Stockholders’ Equity
|
$16,140
|
$15,486
|
Selected Comparative Historical Financial Data
|
For the Quarter Ended/ For the Nine Months Ended/For the
|
Year Ended
|
||||||||
|
$(000s)
|
Q3’12
|
Q3’11
|
Q3’12
|
Q3’11
|
2011
|
2010
|
2009
|
||
|
Total Revenues
|
$5,007
|
$5,921
|
17,744
|
13,171
|
$19,388
|
$ 16,705
|
$13,834
|
||
|
Cost of sales
|
3,278
|
3,251
|
10,112
|
6,524
|
9,998
|
8,604
|
7,974
|
||
|
Gross Profit
|
1,729
|
2,670
|
7,632
|
6,647
|
9,390
|
8,101
|
5,860
|
||
|
34.5%
|
45.1%
|
43.0%
|
50.5%
|
48.4%
|
48.5%
|
42.4%
|
|||
|
R&D Expense
|
1,006
|
1,242
|
3,364
|
3,697
|
4,878
|
2,586
|
2,884
|
||
|
SG&A Expense
|
1,208
|
949
|
3,522
|
2,413
|
3,424
|
2,941
|
2,659
|
||
|
Operating Income
|
(485)
|
479
|
746
|
537
|
1,088
|
2,574
|
317
|
||
|
Other Inc. (Expense)
|
(1)
|
(3)
|
(2)
|
(9)
|
(12)
|
(15)
|
(8)
|
||
|
Net Income -PreTax
|
(4860
|
476
|
744
|
528
|
1,076
|
2,559
|
309
|
||
|
Inc. Tax(Ben.) Prov.
|
(193)
|
-
|
295
|
-
|
(5,133)
|
-
|
-
|
||
|
Net Income (Loss)
|
$(293)
|
$476
|
$449
|
$528
|
$6,209
|
||||
|
Net Income(Loss) - per Share
|
$0.04
|
$0.06
|
0.06
|
.07
|
$0.10
|
$ 0.04
|
$ 0.00
|
||
|
Wt. Avg. No. Shares (MM)
|
8.001
|
7.913
|
7.974
|
7.861
|
63.328
|
62.103
|
61.946
|
||
|
Working capital
|
$6,841
|
$5,281
|
$6,841
|
$5,281
|
6,134
|
$ 4,560
|
$ 1,494
|
||
|
Total assets
|
16,140
|
10,099
|
16,140
|
10,099
|
15,486
|
9,086
|
6,315
|
||
|
Total liabilities
|
2,856
|
3,345
|
2,856
|
3,345
|
2,991
|
3,277
|
3,227
|
||
|
Equity
|
13,284
|
6,754
|
13,284
|
6,754
|
12,495
|
5,809
|
3,088
|
||
|
Chembio Diagnostics, Inc.
|
Investor Relations
|
Company Contact
|
|
3661 Horseblock Road
|
Lippert-Heilshorn & Associates
|
Susan Norcott
|
|
Medford, NY 11763
|
Anne-Marie Fields, Vice President
|
631-924-1135 x125
|
|
Ph. 631-924-1135
|
(212) 838-3777
|
snorcott@chembio.com
|
|
Fax 631-924-2065
|
AFields@lhai.com
|
|
|
www.chembio.com
|
PAGE 2 – See Graphics
DPP® Technology
Competitive Advantages For POC Testing
• Improved Sensitivity - enabled by more efficient binding method
• Easier Multiplexing - due to even and direct distribution of sample to multiple test lines
• Enhanced Sample Control - as result of independent sample migration path
• Clearer Results - efficient binding allows for improved functionality of instruments for reading and reporting of qualitative or quantitative results
Chembio’s Dual Path Platform (DPP®) Patented in 2007 (see graphic)
Chembio’s Lateral Flow Rapid HIV Tests Marketed Exclusively in the USA by Alere North America, Inc.
Senior Management Team
Lawrence A. Siebert, Chairman & CEO, over 25 years of management and financing experience
Richard J. Larkin, CFO, over 25 years of operational and financial experience
Javan Esfandiari, SVP R&D, over 15 years of experience in development of in-vitro point-of- care products
Independent Members of Board of Directors
Katherine Davis - Former Lieutenant Governor and numerous other leadership positions for the State of Indiana; former senior executive of Cummins, Inc. (NYSE:CMI)
Dr. Barbara DeBuono – Former New York Commissioner of Health and Rhode Island Director of Health; other positions in domestic and international medical services
Dr. Peter Kissinger – Has founded and/or led 3 biotechnology and/or biomedical technology companies, including a publicly-traded NASDAQ company
Dr. Gary Meller - Broad experience in medical and information technology and pharmaceutical product development
Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which is subject to risks and uncertainties. Please refer to Chembio Diagnostic’s Inc. most recent Form 10-K and Forms 10-Q for additional information about the Company and related risks. –May 2012.